Online citations, reference lists, and bibliographies.

Molecular Mechanisms Whereby Immunomodulatory Drugs Activate Natural Killer Cells: Clinical Application.

Toshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, Klaus Podar, Hiroshi Yasui, Noopur Raje, S Kumar, Dharminder Chauhan, Steven P Treon, Paul Richardson, Kenneth C. Anderson
Published 2005 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Thalidomide and immunomodulatory drugs (IMiDs), which target multiple myeloma (MM) cells and the bone marrow microenvironment, can overcome drug resistance. These agents also have immunomodulatory effects. Specifically, we have reported that thalidomide increased serum interleukin-2 (IL-2) levels and natural killer (NK) cell numbers in the peripheral blood of responding MM patients. In this study, we investigated the mechanisms whereby IMiDs augment NK cell cytotoxicity. NK cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells cultured with IMiDs were examined in the presence or absence of anti-IL-2 antibody, ciclosporin A or depletion of CD56-positive cells. IMiDs-induced signalling pathways, triggering IL-2 transcription in T cells, were also delineated. IMiDs facilitated the nuclear translocation of nuclear factor of activated T cells-2 and activator protein-1 via activation of phosphoinositide-3 kinase signalling, with resultant IL-2 secretion. IMiDs enhanced both NK cell cytotoxicity and ADCC induced by triggering IL-2 production from T cells. These studies defined the mechanisms whereby IMiDs trigger NK cell-mediated tumour-cell lysis, further supporting their therapeutic use in MM.

This paper is referenced by
Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma.
Steven P Treon (2008)
Immunotherapeutic approaches in ocular inflammatory diseases.
Shree Kala Kurup (2005)
Translating the anti-myeloma activity of Natural Killer cells into clinical application.
Cinzia Fionda (2018)
Direct potentiation of NK cell cytotoxicity by 8-azaguanine with potential antineoplastic activity.
Nayoung Kd Kim (2019)
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice
Roberto Castelli (2012)
A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia
Emmanuelle Tavernier-Tardy (2017)
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway
Davide Bommarito (2016)
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
Aude Le Roy (2018)
Immunomodulatory Effects of Small-Molecule Compounds: Impact on Hematologic Malignancies
Noriyoshi Iriyama (2017)
Novel agents in mantle cell lymphoma
David Tucker (2017)
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
D. Michael Benson (2015)
Pharmacological targeting of natural killer cells for cancer immunotherapy
Kiho Miyazato (2020)
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Rekha Pal (2010)
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
Douglas W. Sborov (2015)
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice
Pier Luigi Zinzani (2015)
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
Maria Pia Abruzzese (2019)
Thalidomide in multiple myeloma
Ramón García-Sanz (2006)
Immunotherapy in multiple myeloma.
Simon James Harrison (2020)
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Amir A Toor (2012)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
Meletios Athanasios Dimopoulos (2018)
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma
Noopur S. Raje (2006)
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
Laurie Besson (2018)
The Statistical Analysis Plan
Karl E. Peace (2010)
Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies
Camille Guillerey (2016)
Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
Thanh-Nhan Nguyen-Pham (2015)
POMALIDOMID – nowy immunomodulujący lek w terapii szpiczaka plazmocytowego
Artur Jurczyszyn (2014)
Natural killer cells for osteosarcoma.
Nidale Tarek (2014)
Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide.
M Huang (2011)
The therapeutic role of natural killer cells in multiple myeloma
Ghulam Rehman Mohyuddin (2019)
Immunologic microenvironment and personalized treatment in multiple myeloma
Marco Rossi (2013)
Immunotherapy for multiple myeloma
Jacalyn Rosenblatt (2014)
Amphotericin B, an Anti-Fungal Medication, Directly Increases the Cytotoxicity of NK Cells
Nayoung Kim (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar